今日の臨床サポート 今日の臨床サポート

著者: 大村和弘 東京慈恵会医科大学耳鼻咽喉科学教室

監修: 森山寛1) 東京慈恵会医科大学附属病院

監修: 小島博己2) 東京慈恵会医科大学 耳鼻咽喉科

著者校正/監修レビュー済:2022/12/21
参考ガイドライン:
  1. 日本頭頸部学会:頭頸部癌診療ガイドライン 2022年版
患者向け説明資料

改訂のポイント:
  1. 嗅神経芽細胞腫への治療方針に関しては特に大きな変更点はなく、手術加療が中心となる中で、手術単独治療または手術+放射線治療を組み合わせるか、手術不可能な場合は、抗がん剤+放射線治療または重粒子線治療の選択肢がある。

概要・推奨   

  1. 鼻副鼻腔腫瘍の代表的な良性腫瘍は血管腫である。
  1. 良性腫瘍の中で悪性化する可能性のあるものに、内反性乳頭腫や多形腺腫がある。
  1. 悪性腫瘍では扁平上皮癌が最も多いが、それ以外にも嗅神経芽細胞腫を含めて多彩な病理組織型の悪性腫瘍が発生する。
アカウントをお持ちの方はログイン
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が
  1. 閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。閲覧にはご契約が必要となります。

これより先の閲覧には個人契約のトライアルまたはお申込みが必要です。

最新のエビデンスに基づいた二次文献データベース「今日の臨床サポート」。
常時アップデートされており、最新のエビデンスを各分野のエキスパートが豊富な図表や処方・検査例を交えて分かりやすく解説。日常臨床で遭遇するほぼ全ての症状・疾患から薬剤・検査情報まで瞬時に検索可能です。

まずは15日間無料トライアル
本サイトの知的財産権は全てエルゼビアまたはコンテンツのライセンサーに帰属します。私的利用及び別途規定されている場合を除き、本サイトの利用はいかなる許諾を与えるものでもありません。 本サイト、そのコンテンツ、製品およびサービスのご利用は、お客様ご自身の責任において行ってください。本サイトの利用に基づくいかなる損害についても、エルゼビアは一切の責任及び賠償義務を負いません。 また、本サイトの利用を以て、本サイト利用者は、本サイトの利用に基づき第三者に生じるいかなる損害についても、エルゼビアを免責することに合意したことになります。  本サイトを利用される医学・医療提供者は、独自の臨床的判断を行使するべきです。本サイト利用者の判断においてリスクを正当なものとして受け入れる用意がない限り、コンテンツにおいて提案されている検査または処置がなされるべきではありません。 医学の急速な進歩に鑑み、エルゼビアは、本サイト利用者が診断方法および投与量について、独自に検証を行うことを推奨いたします。

文献 

Rui Peng, Andrew Thamboo, Garret Choby, Yifei Ma, Bing Zhou, Peter H Hwang
Outcomes of sinonasal inverted papilloma resection by surgical approach: an updated systematic review and meta-analysis.
Int Forum Allergy Rhinol. 2019 Jun;9(6):573-581. doi: 10.1002/alr.22305. Epub 2019 Feb 12.
Abstract/Text BACKGROUND: Selecting the optimal surgical approach for resection of sinonasal inverted papilloma (SIP) remains a challenge, with endoscopic, external, and combined approaches being utilized. This systematic review was conducted as an update to a 2006 systematic review to determine the preferred surgical approach for tumor control.
METHODS: The study protocol was developed a priori following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process. Data were collected and outcomes were analyzed according to surgical approach and sites of tumor involvement.
RESULTS: A total of 96 papers and 4134 SIP patients were included. The overall recurrence rate was 12.80% (322/2515) for the endoscopic approach group, 16.58% (182/1098) for the external approach group, and 12.60% (65/516) for the combined approach group. Meta-analysis by random effects model showed that the summarized risk ratio (RR) of recurrence was 0.61 (95% confidence interval [CI], 0.44 to 0.85, p = 0.003), I2 = 37.95% for the endoscopic vs external approach; 0.98 (95% CI, 0.69 to 1.39, p = 0.901), I2 = 9.06% for the endoscopic vs combined approach; 1.61 (95% CI, 1.06 to 2.43, p = 0.025), I2 = 0.00% for the external vs combined approach. After adjusting for publication bias, the adjusted RRs were 0.66 (p = 0.014) for endoscopic vs external; 0.99 (p = 0.955) for endoscopic vs combined; and 1.33 (p = 0.224) for external vs combined.
CONCLUSION: An enlarging and maturing body of literature continues to indicate that endoscopic approaches result in significantly lower recurrence rates than open approaches for surgical resection of SIP.

© 2019 ARS-AAOA, LLC.
PMID 30748098
Kazuhiro Omura, Kazuhiro Nomura, Ryosuke Mori, Yudo Ishii, Satoshi Aoki, Teppei Takeda, Kosuke Tochigi, Yasuhiro Tanaka, Nobuyoshi Otori, Hiromi Kojima
Optimal Multiple-Layered Anterior Skull Base Reconstruction Using a 360° Suturing Technique.
Oper Neurosurg (Hagerstown). 2022 Jan 1;22(1):e1-e6. doi: 10.1227/ONS.0000000000000013.
Abstract/Text BACKGROUND: Advances in technique and instrumentation have improved outcomes after resection of anterior skull base tumors. However, cerebrospinal fluid (CSF) leak occurs in 4%-20% of patients. To reduce the risk of CSF leak, we have developed a novel reconstruction technique that consists of a 4-layered graft with patchwork suturing and hard material.
OBJECTIVE: To evaluate the effectiveness of this reconstruction technique when used for resection of anterior skull base tumors.
METHODS: This case series included 59 patients with anterior skull base tumors in whom the 4-layered closure technique was used. The main outcome measures were complications, including CSF leak, meningitis, postoperative bleeding, and infection.
RESULTS: There were no CSF leak cases or serious complications after closure of the anterior skull base using the 4-layered technique.
CONCLUSION: Closure of the anterior skull base in 4 layers prevented CSF leak and was not associated with any serious complications. However, further studies in larger numbers of patients are needed to confirm our outcomes using this closure method.

Copyright © Congress of Neurological Surgeons 2021. All rights reserved.
PMID 34982903
Ashley C Mays, Diana Bell, Renata Ferrarotto, Jack Phan, Dianna Roberts, Clifton D Fuller, Steven J Frank, Shaan M Raza, Michael E Kupferman, Franco DeMonte, Ehab Y Hanna, Shirley Y Su
Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb.
Laryngoscope. 2018 Jun;128(6):1274-1280. doi: 10.1002/lary.26908. Epub 2017 Dec 11.
Abstract/Text OBJECTIVE: Compare outcomes of patients with olfactory neuroblastoma (ONB) without skull base involvement treated with and without resection of the dura and olfactory bulb.
METHODS: Retrospective review of ONB patients treated from 1992 to 2013 at the MD Anderson Cancer Center (The University of Texas, Houston, Texas, U.S.A.). Primary outcomes were overall and disease-free survival.
RESULTS: Thirty-five patients were identified. Most patients had Kadish A/B. tumors (97%), Hyams grade 2 (70%), with unilateral involvement (91%), and arising from the nasal cavity (68%). Tumor involved the mucosa abutting the skull base in 42% of patients. Twenty-five patients (71%) received surgery and radiation, whereas the remainder had surgery alone. Five patients (14%) had bony skull base resection, and eight patients (23%) had resection of bony skull base, dura, and olfactory bulb. Surgical margins were grossly positive in one patient (3%) and microscopically positive in four patients (12%). The 5- and 10-year overall survival were 93% and 81%, respectively. The 5- and 10-year disease-free survival (DFS) were 89% and 78%, respectively. Bony cribriform plate resection was associated with better DFS (P = 0.05), but dura and olfactory bulb resection was not (P = 0.11). There was a trend toward improved DFS in patients with negative resection margins (P = 0.19). Surgical modality (open vs. endoscopic) and postoperative radiotherapy did not impact DFS.
CONCLUSION: Most Kadish A/B ONB tumors have low Hyams grade, unilateral involvement, and favorable survival outcomes. Resection of the dura and olfactory bulb is not oncologically advantageous in patients without skull base involvement who are surgically treated with negative resection margins and cribriform resection.
LEVEL OF EVIDENCE: 4. Laryngoscope, 128:1274-1280, 2018.

© 2017 The American Laryngological, Rhinological and Otological Society, Inc.
PMID 29226334
J H Krouse
Development of a staging system for inverted papilloma.
Laryngoscope. 2000 Jun;110(6):965-8. doi: 10.1097/00005537-200006000-00015.
Abstract/Text OBJECTIVES: Inverted papillomas of the nose and sinuses are uncommon neoplasms. In the past decade there has been a trend toward the use of endoscopic surgical techniques in the management of these tumors, in contrast to the extensive open procedures recommended previously. This trend has not been without controversy, given the association of inverted papillomas with malignancy. It has been difficult to compare surgical approaches to these neoplasms, because of the absence of a uniformly applied staging system representing the extent of disease. It was the purpose of this study to develop such a system that could be easily applied in outcomes research.
STUDY DESIGN: This study involved an integrated literature review and a synthesis of findings from a number of studies.
METHODS: Previous and current clinical studies examining the treatment of inverted papilloma were reviewed. Findings were organized, and a staging system was framed based on this review.
RESULTS: A simple, easily applied staging system was developed based on the extent of tumor involvement noted on endoscopic examination of the nasal cavity and computed tomography (CT) scan evaluation.
CONCLUSIONS: Stage I disease is limited to the nasal cavity alone. Stage II disease is limited to the ethmoid sinuses and medial and superior portions of the maxillary sinuses. Stage III disease involves the lateral or inferior aspects of the maxillary sinuses or extension into the frontal or sphenoid sinuses. Stage IV disease involves tumor spread outside the confines of the nose and sinuses, as well as any malignancy.

PMID 10852514
薬剤監修について:
オーダー内の薬剤用量は日本医科大学付属病院 薬剤部 部長 伊勢雄也 以下、渡邉裕次、井ノ口岳洋、梅田将光および日本医科大学多摩永山病院 副薬剤部長 林太祐による疑義照会のプロセスを実施、疑義照会の対象については著者の方による再確認を実施しております。
※薬剤中分類、用法、同効薬、診療報酬は、エルゼビアが独自に作成した薬剤情報であり、 著者により作成された情報ではありません。
尚、用法は添付文書より、同効薬は、薬剤師監修のもとで作成しております。
※同効薬・小児・妊娠および授乳中の注意事項等は、海外の情報も掲載しており、日本の医療事情に適応しない場合があります。
※薬剤情報の(適外/適内/⽤量内/⽤量外/㊜)等の表記は、エルゼビアジャパン編集部によって記載日時にレセプトチェックソフトなどで確認し作成しております。ただし、これらの記載は、実際の保険適応の査定において保険適応及び保険適応外と判断されることを保証するものではありません。また、検査薬、輸液、血液製剤、全身麻酔薬、抗癌剤等の薬剤は保険適応の記載の一部を割愛させていただいています。
(詳細はこちらを参照)
著者のCOI(Conflicts of Interest)開示:
大村和弘 : 未申告[2024年]
監修:森山寛 : 未申告[2024年]
監修:小島博己 : 特に申告事項無し[2024年]

ページ上部に戻る

鼻・副鼻腔腫瘍(乳頭腫・血管腫・癌・嗅神経芽細胞腫)

戻る